Nov 01, 2019 / 04:00AM GMT
Presentation and Definitive Agreement for Strategic Alliance with Roivant Sciences
Nov 01, 2019 / 04:00AM GMT
=====================
Corporate Participants
=====================
* Hiroshi Nomura
Sumitomo Dainippon Pharma Co., Ltd. - CEO, President & Representative Director
=====================
Conference Call Participants
=====================
* Fumiyoshi Sakai
Crédit Suisse AG, Research Division - Research Analyst
* Kazuaki Hashiguchi
Daiwa Securities Co. Ltd., Research Division - Research Analyst
* Motoya Kohtani
Nomura Securities Co. Ltd., Research Division - Senior Analyst
* Seiji Wakao
Mitsubishi UFJ Morgan Stanley Securities Co., Ltd., Research Division - Senior Analyst
* Shinichiro Muraoka
Morgan Stanley, Research Division - Research Analyst
* Stephen Marks
Jefferies LLC - Investment Banking Analyst
* Yasuhiro Nakazawa
SMBC Nikko Securities Inc., Research Division - Senior Analyst
* Myrtle Potter;CEO
* Vivek Ramaswamy
Roivant
Roivant Sciences Ltd
(NAS:ROIV)
$
11.57
-0.26 (-2.2%)
Market Cap: 8.56 Bil
Enterprise Value: 3.46 Bil
PE Ratio: 2.08
PB Ratio: 1.58
GF Score: 59/100 Q2 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Presentation and Definitive Agreement for Strategic Alliance with Roivant Sciences Transcript
Nov 01, 2019 / 04:00AM GMT
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot